Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

The global biotech industry is booming, and by 2025 it will reach an estimated market worth of $729B. But while great innovation is driven by emerging biotechs, these companies often lack resources, ...

Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...

Complex regional pain syndrome (CRPS) is a rare but severe neuropathic pain condition that causes intense, long-lasting pain, often following an injury or surgery. Patients frequently report some of ...

The month of September was a big one for mergers and acquisitions (M&As) in the biotech industry. There were four billion-dollar acquisitions that were the most notable. The top buyout was Danish ...

The U.K. has had a stronghold on the biopharma and healthcare industry for a long time and remains one of the top hubs for life science research. So, Merck’s decision to back out of its $1 billion ...